Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) FCF Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed FCF Margin for 5 consecutive years, with 44.35% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 71.0% to 44.35% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 60.96% through Dec 2025, up 2655.0% year-over-year, with the annual reading at 61.46% for FY2025, 2605.0% up from the prior year.
  • FCF Margin for Q4 2025 was 44.35% at Rhythm Pharmaceuticals, up from 51.9% in the prior quarter.
  • The five-year high for FCF Margin was 422.45% in Q4 2022, with the low at 95837.14% in Q1 2021.
  • Average FCF Margin over 5 years is 5990.94%, with a median of 143.44% recorded in 2023.
  • The sharpest move saw FCF Margin surged 9224842bps in 2022, then plummeted -54370bps in 2023.
  • Over 5 years, FCF Margin stood at 2231.15% in 2021, then surged by 119bps to 422.45% in 2022, then tumbled by -129bps to 121.24% in 2023, then soared by 63bps to 45.05% in 2024, then grew by 2bps to 44.35% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 44.35%, 51.9%, and 48.07% for Q4 2025, Q3 2025, and Q2 2025 respectively.